Skip to main content

Table 3 Exacerbation severity and treatment by baseline biomarker profile

From: Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease

  Number of exacerbation Hospitalized exacerbation
N (%)
p-value Exacerbation treated with antibiotics
N (%)
p-value Exacerbation treated with systemic corticosteroids
N (%)
p-value
LPA16:0
 Low 32 6 (18.8)   28 (87.5)   29 (90.6)  
 Medium 31 4 (12.9) 0.42 23 (74.2) 0.058 29 (93.5) 0.89
 High 19 1 (5.3)   11 (57.9)   17 (89.5)  
LPA18:0
 Low 31 4 (12.9)   24 (77.4)   28 (90.3) 1.0
 Medium 30 5 (16.7) 0.85 24 (80.0) 0.58 28 (93.3)  
 High 21 2 (9.5)   14 (66.7)   19 (90.5)  
LPA18:1
 Low 25 2 (8.0)   22 (88.0)   22 (88.0)  
 Medium 34 7 (20.6) 0.36 26 (76.5) 0.10 33 (97.1) 0.32
 High 23 2 (8.7)   14 (60.9)   20 (87.0)  
LPA18:2
 Low 29 4 (13.8)   21 (72.4)   27 (93.1)  
 Medium 30 4 (13.3) 1.0 26 (86.7) 0.18 27 (90.0) 1.0
 High 23 3 (13.0)   15 (65.2)   21 (91.3)  
LPA20:4
 Low 32 5 (15.6)   25 (78.1)   29 (90.6)  
 Medium 33 4 (12.1) 0.92 24 (72.7) 0.944 33 (100) 0.0087*
 High 17 2 (11.8)   13 (76.5)   13 (76.5)  
  1. Fisher’s Exact test p-values shown